- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06453928
위험에 처한 제1형 당뇨병 연구에서 기술 시작 (STAR-T1D)
제1형 당뇨병 위험에 대한 시작 기술(STAR-T1D) 연구
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Estelle M Everett, MD, MHS
- 전화번호: 310-267-0625
- 이메일: eeverett@mednet.ucla.edu
연구 장소
-
-
California
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA
-
연락하다:
- Rebecca Lopez, BA
- 전화번호: (310) 882-0033
- 이메일: rebeccalopez@mednet.ucla.edu
-
연락하다:
- Erin E Shaw, B.S.
- 이메일: EEShaw@mednet.ucla.edu
-
Sylmar, California, 미국, 91342
- 모병
- Olive View-UCLA Medical Center
-
연락하다:
- Hugo Torres, MD
- 전화번호: 747-210-3000
- 이메일: HATorres@mednet.ucla.edu
-
Torrance, California, 미국, 90502
- 모병
- Harbor-UCLA Medical Center
-
연락하다:
- Joyce A Graham
- 전화번호: (310) 222-1870
- 이메일: jgraham@lundquist.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Type 1 Diabetes
- A1c ≥ 8.0%
- Not insulin pump user
- Primary language of English or Spanish
- Have medical insurance coverage
Exclusion Criteria:
- No measured A1c in the past year
- Have comorbidities that can result in inaccurate hemoglobin A1c
- Have cognitive, physical or mental impairment precluding diabetes technology use
- Limited life expectancy (<1 year)
- Pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Hybrid Closed Loop Insulin Pump System
Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Patients will be started on an automated insulin delivery system. |
|
간섭 없음: Control
Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of screened participants that are eligible
기간: 6 months
|
Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data. |
6 months
|
|
Proportion of enrolled participants that are randomized
기간: 6 months
|
Randomized among enrolled, and receiving allocated intervention among randomized. |
6 months
|
|
Proportion of average time delay to enrollment
기간: 6 months
|
Average time delay from screening to enrollment. |
6 months
|
|
Proportion of retention among participants randomized to the Intervention Group
기간: 6 months
|
Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized. |
6 months
|
|
Proportion of retention among participants randomized
기간: 6 months
|
Participants lost to follow-up among those initially randomized. |
6 months
|
|
Proportion of retention among participants randomized
기간: 6 months
|
Retention rates by participants completing all research assessments among randomized. |
6 months
|
|
Number of participants who adhere to assigned treatment
기간: 6 months
|
Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed. Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. |
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in A1c
기간: 6 months
|
Serum Hemoglobin A1c laboratory measurement |
6 months
|
|
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
기간: 6 months
|
Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl. |
6 months
|
|
Mean Diabetes Ketoacidosis Episodes Incidence
기간: 6 months
|
Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews. |
6 months
|
|
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
기간: 6 months
|
Number of diabetes related ED visits or hospitalizations |
6 months
|
|
Treatment Burden and Satisfaction: Diabetes Distress
기간: 6 months
|
Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5. |
6 months
|
|
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
기간: 6 months
|
Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life. |
6 months
|
|
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
기간: 6 months
|
Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each. |
6 months
|
|
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
기간: 6 months
|
Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome. WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9. |
6 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 22-000236
- 5K23DK132482-02 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .